Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds RBC Capital Reiterates Outperform on Viracta Therapeutics, Maintains $8 Price Target

RBC Capital Reiterates Outperform on Viracta Therapeutics, Maintains $8 Price Target

RBC Capital analyst Gregory Renza reiterates Viracta Therapeutics (NASDAQ:VIRX) with a Outperform and maintains $8 price target.

byBenzinga Newsdesk

March 14, 2023

1 minute read

RBC Capital analyst Gregory Renza reiterates Viracta Therapeutics (NASDAQ:VIRX) with a Outperform and maintains $8 price target.

International Paper Earnings Exceed Estimates In Q2 On Cost Management Strategies

By Nabaparna Bhattacharya

July 27, 12:33 PM

International Paper Company (NYSE: IP) second-quarter FY23 sales decreased 13.1% year-on-year to $4.68 billion,

Analyst Ratings

Where GoDaddy Stands With Analysts

By Benzinga Insights

April 11, 4:01 PM

Over the past 3 months, 9 analysts have published their opinion on GoDaddy (NYSE:GDDY) stock. These analysts are…

GDDY

Why MSP Recovery Stock Popped Today

By Ryan Gustafson

October 26, 3:50 PM

MSP Recovery, Inc. (NASDAQ: LIFW) shares are trading higher on Thursday after company CEO John Hasan Ruiz bought 467,290 shares at an average price of $1.07 per share.

LIFW

$100 Invested In SunPower 10 Years Ago Would Be Worth This Much Today

By Benzinga Insights

September 7, 4:40 PM

SunPower (NASDAQ:SPWR) has outperformed the market over the past 10 years by 13.57% on an annualized basis producing an average annual return of 24.27%. Currently, SunPower has a market capitalization of $4.76 billion.

SPWR

RBC Capital Reiterates Outperform on Viracta Therapeutics, Maintains $8 Price Target

Related Posts

International Paper Earnings Exceed Estimates In Q2 On Cost Management Strategies

Where GoDaddy Stands With Analysts

Why MSP Recovery Stock Popped Today

$100 Invested In SunPower 10 Years Ago Would Be Worth This Much Today